ArticleLancet regional health. Americas2024
Implementation of a mobile health clinic framework for Hepatitis C virus screening and treatment: a descriptive study.
Article in Lancet regional health. Americas, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Comparative Impact of Active Versus Passive Surveillance on Hepatitis C Virus Testing Uptake, Diagnosis and Linkage to Care in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis.Tropical medicine & international health : TM & IH · 2026Pooled it
- No Roadblocks: How Mobile Primary Care Navigates Barriers to Health Access.International journal of environmental research and public health · 2026Article
- Optimizing mobile health clinic placement via geospatial modeling.Public health in practice (Oxford, England) · 2026Article
- Cost-Effectiveness of Point-of-Care Hepatitis C Virus RNA Testing in the US.JAMA network open · 2026Article
- Identifying and Linking to Care and Treatment Persons With Hepatitis C Who Were Lost to Follow-Up, Georgia 2023-2024.Journal of viral hepatitis · 2026Article
- Mobile Interventions and Telemedicine for Hepatitis C Elimination.JAMA network open · 2026Article
- A multi-perspective assessment of knowledge, attitudes, and barriers to viral hepatitis care in Ghana.Frontiers in cellular and infection microbiology · 2026Article
- Building a Low-Threshold Model for HCV Diagnosis and Treatment Among Formerly Incarcerated Patients in Alabama.Journal of general internal medicine · 2025Article
- Navigating Hepatitis C care: Knowledge gaps and access barriers among young women who inject drugs in rural Appalachia.PloS one · 2025Article
- Predicting mobile health clinic utilization for COVID-19 vaccination in South Carolina: A statistical framework for strategic resource allocation.PLOS global public health · 2025Article
- Understanding Barriers to Hepatitis C Antiviral Treatment in Low-Middle-Income Countries.Healthcare (Basel, Switzerland) · 2024Review
- Mobile health clinics for distribution of vaccinations to underserved communities during health emergencies: A COVID-19 case study.Public health in practice (Oxford, England) · 2024Article
- Elimination of HCV Infection: Recent Epidemiological Findings, Barriers, and Strategies for the Coming Years.Viruses · 2024Review
- Identification of factors associated with opioid-related and hepatitis C virus-related hospitalisations at the ZIP code area level in the USA: an ecological and modelling study.The Lancet. Public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Background: Although treatment for Hepatitis C Virus (HCV) is effective, individuals face access barriers. The utility of mobile health clinics (MHC), effective mechanisms for providing healthcare to underserved populations, is understudied for HCV-related interventions. We aimed to describe implementation of, and factors associated with, screening and treatment via MHCs. Methods: Clemson Rural Health implemented a novel MHC program to reach and treat populations at-risk for HCV with a focus on care for uninsured individuals. We examined HCV screening and treatment initiation/completion indicators between May 2021 and January 2023. Findings: Among 607 individuals screened across 31 locations, 94 (15.5%) tested positive via antibody and viral load testing. Treatment initiation and completion rates were 49.6% and 86.0%, respectively. Among those screened, the majority were male (57.5%), White (61.3%; Black/Hispanic: 28.2%/7.7%), and without personal vehicle as primary transportation mode (54.4%). Injection drug use (IDU) was 27.2% and uninsured rate was 42.8%. Compared to HCV-negative, those infected included more individuals aged 30-44 (52.1% vs. 36.4%, Interpretation: The MHC framework successfully reaching its target population: at-risk individuals with access barriers to healthcare. The high HCV screening and treatment initiation/completion rates demonstrate the utility of MHCs as effective and acceptable intervention settings among historically difficult-to-treat populations. Funding: Gilead Sciences, Inc., and SC Center for Rural and Primary Healthcare.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.